Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
Discontinuing Depo-Provera After Diagnosis
The updated FDA label (December 2025) instructs healthcare providers to "discontinue Depo-Provera CI if a meningioma is diagnosed." Stopping MPA exposure removes the hormonal stimulus that drives meningioma growth through progesterone receptor activation. Some patients have experienced tumor stabilization or even shrinkage after discontinuing progestin medications.
Safer Contraceptive Options
Copper IUD (Paragard) — hormone-free, highly effective, 10-year duration. Barrier methods (condoms, diaphragm) — no hormonal exposure. Tubal ligation / vasectomy — permanent options. Non-progestin hormonal options should be discussed carefully with your doctor given the progesterone receptor mechanism.
What About Other Progestins?
The EMA review noted that the meningioma risk is primarily associated with high-dose and depot (injected) MPA. Low-dose progestin contraceptives (hormonal IUDs like Mirena, progestin-only pills) have not shown the same magnitude of risk. However, given the progesterone receptor mechanism, women diagnosed with meningioma should discuss all hormonal contraception with their doctor.
Ongoing Monitoring
After a meningioma diagnosis, regular MRI monitoring is standard of care — typically every 6–12 months initially, then annually. If you discontinue Depo-Provera and the tumor remains stable, your neurologist may extend monitoring intervals. Document all monitoring visits and results for your legal case.
Research & evidence
Scientific Evidence
Medroxyprogesterone Acetate and Meningioma: A Global Issue
Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health
View on PubMedUse of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma
Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ
View on PubMedThe Association between Medroxyprogesterone Acetate Exposure and Meningioma
Griffin BR et al. (2024). Cancers
View on PubMedFAQ
Frequently Asked Questions
Dive deeper
Related Guides
- Depo-Provera Meningioma Brain TumorMeningioma — a tumor in the tissue surrounding the brain — is the primary injury in Depo-Provera lawsuits. Studies show long-term users face up to a 5.6x increased risk. The tumor can cause seizures, vision loss, and require major brain surgery.
- Depo-Provera Brain Tumor SymptomsMeningioma symptoms develop gradually and include persistent headaches, vision changes, seizures, and cognitive decline. If you used Depo-Provera and experience these symptoms, request brain imaging from your doctor.
- Depo-Provera Long-Term Use RisksLong-term Depo-Provera use carries multiple serious risks: meningioma brain tumors (up to 5.6x risk), significant bone density loss (black box warning), weight gain, depression, and delayed return to fertility. The FDA recommends limiting use to 2 years.
- Depo-Provera Settlement AmountsNo Depo-Provera meningioma cases have settled or gone to trial yet. Projected settlements based on comparable pharmaceutical brain injury litigation suggest $75,000 to $1.5 million+ depending on injury severity.
- Pfizer Depo-Provera LawsuitPfizer inherited Depo-Provera when it acquired Pharmacia & Upjohn in 2002. Despite international warnings dating to 2015, Pfizer did not add a U.S. meningioma warning until December 2025. Plaintiffs allege a pattern of delayed safety action prioritizing revenue over patient safety.
- Depo-Provera Military VeteransMilitary women were disproportionately prescribed Depo-Provera due to its convenience for deployment. If you received Depo-Provera during military service and were later diagnosed with a meningioma, you may be eligible for both civil lawsuit compensation and VA benefits.
- Depo-Provera MRI ScreeningCurrent guidelines do not recommend routine MRI screening for asymptomatic Depo-Provera users. However, the updated FDA label instructs providers to monitor for meningioma symptoms. If you have symptoms, request brain imaging immediately.
The full investigation